Technical Data
A1059-51B
Aggrecan (Aggrecan Core Protein, ACAN, AGCAN, Aggrecan 1, Aggrecan1, AGC 1, AGC1, AGC1 Protein, Antigen Identified by Monoclonal A0122, Cartilage Specific Proteoglycan Core Protein, CSPCP, CSPGCP, Chondroitin Sulfate Proteoglycan 1, Chondroitin Sulfate Pr
Description:
A1059-51B recognises human aggrecan, a proteoglycan and member of the aggrecan/versican proteoglycan family, which forms a major component of the extracellular matrix (ECM) of both cartilage and the central nervous system (CNS). Studies using a panel of core protein-directed antibodies against human aggrecan, revealed the distribution of different aggrecan isoforms within the CNS, and sub-divided the isoforms into clusters 1-5 accordingly. These studies also showed a difference in the relative abundance of these isoforms when comparing brain and cartilage tissues.

Applications:
Suitable for use in ELISA, Immunohistochemistry and Western Blot. Other applications not tested.

Recommended Dilution:
Immunohistochemistry: Paraffin and frozen sections
Optimal dilutions to be determined by the researcher.

Hybridoma:
NS1 myeloma cells with spleen cells from Balb/c mice.

Positive Control:
Cerebral cortex

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
TypeIsotypeCloneGrade
MabIgG110B83Supernatant
SizeStorageShippingSourceHost
2ml-20CBlue IceHumanMouse
Concentration:
Not determined
Immunogen:
Purified human articular cartilage aggrecan
Purity:
Supernatant
Form
Supplied as a liquid in PBS, 0.09% sodium azide.
Specificity:
Recognizes human articular cartilage aggrecan. Recognizes an epitope within the 0-glycan attachment site and has been identified as a cluster 2 isoform. Species Crossreactivity: bovine. Does not react with chicken, fish, rat.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.